SAMSUNG PHARMACEUTICAL.CO.,Ltd.

As of June 30, 2026, SAMSUNG PHARMACEUTICAL.CO.,Ltd. carries a market capitalization of 125.46B, placing it among publicly traded companies globally. Its enterprise value stands at 134.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, SAMSUNG PHARMACEUTICAL.CO.,Ltd. has 94.12M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.94, and the price-to-book ratio stands at 1.74.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 134.50B versus a market cap of 125.46B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, SAMSUNG PHARMACEUTICAL.CO.,Ltd. maintains a current ratio of 0.77, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.74, indicating elevated leverage, while an interest coverage ratio of -10.41 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, SAMSUNG PHARMACEUTICAL.CO.,Ltd. posted a negative return on equity (ROE) of -98.21, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -78.99, reflecting losses generated across the asset base. The company generates approximately 492.63M in revenue per employee across its workforce of 86.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.17 indicates how many times SAMSUNG PHARMACEUTICAL.CO.,Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, SAMSUNG PHARMACEUTICAL.CO.,Ltd.'s stock has declined approximately 16.98% over the past 52 weeks. The 50-day moving average sits at 1,326.10, while the 200-day moving average is 1,564.25.

Over the twelve months ended June 30, 2026, SAMSUNG PHARMACEUTICAL.CO.,Ltd. generated 42.74B in revenue and converted that into -137.15B in net income, yielding earnings per share of -1,394.67. EBITDA reached -15.33B, while operating income came in at -16.15B.

As of June 30, 2026, SAMSUNG PHARMACEUTICAL.CO.,Ltd. holds 9.56B in cash and equivalents against 18.60B in total debt, resulting in a net debt position of 13.85B. Total book value stands at 72.26B, with working capital of -9.39B providing operational flexibility.

SAMSUNG PHARMACEUTICAL.CO.,Ltd. produced -8.80B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -13.48B in capital expenditures, free cash flow totaled -22.28B - equivalent to -236.71 per share.

Over the twelve months ended June 30, 2026, SAMSUNG PHARMACEUTICAL.CO.,Ltd. posted a gross margin of 36.63, reflecting its pricing power and cost economics. The operating margin of -37.80 and net profit margin of -320.93 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -16.99: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -20.79, meaning SAMSUNG PHARMACEUTICAL.CO.,Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

SAMSUNG PHARMACEUTICAL.CO.,Ltd.'s most recent stock split took place on January 4, 2024 with a 443:491 split ratio.

As of June 30, 2026, SAMSUNG PHARMACEUTICAL.CO.,Ltd. has an Altman Z-Score of 0.85, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.